Reply to the letter by Dr Graham concerning ethical and interpretation issues with vonoprazan-containing H. pylori eradication therapy.

Murakami, Kazunari; Sakurai, Yuuichi; Shiino, Madoka; Funao, Nobuo; Nishimura, Akira; Asaka, Masahiro

Murakami, Kazunari; Sakurai, Yuuichi; Shiino, Madoka; Funao, Nobuo; Nishimura, Akira; Asaka, Masahiro.

Afiliação

Murakami K; Department of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan.
Sakurai Y; Takeda Pharmaceutical Company Ltd., Osaka, Japan.
Shiino M; Takeda Pharmaceutical Company Ltd., Osaka, Japan.
Funao N; Takeda Pharmaceutical Company Ltd., Osaka, Japan.
Nishimura A; Takeda Pharmaceutical Company Ltd., Osaka, Japan.
Asaka M; Health Sciences University of Hokkaido, Hokkaido, Japan.

Gut ; 66(2): 386, 2017 02.

Article em En | MEDLINE | ID: mdl-27196601

Assuntos

Infecções por Helicobacter; Helicobacter pylori; Antibacterianos; Quimioterapia Combinada; Humanos

Palavras-chave

ANTIBIOTIC THERAPY; CLINICAL TRIALS; HELICOBACTER PYLORI INFECTION

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Helicobacter pylori / Infecções por Helicobacter Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google